Cervical cancer continues to be among the most frequent gynaecologic cancers worldwide. The phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) pathway is constitutively activated in cervical cancer. Inositol polyphosphate 4-phosphatase type II (INPP4B) is a phosphoinositide phosphatase and considered a negative regulatory factor of the PI3K/AKT pathway. INPP4B has diverse roles in various tumours, but its role in cervical cancer is largely unknown. In this study, we investi- Inositol polyphosphate 4-phosphatase type II (INPP4B) is a phosphoinositide phosphatase that dephosphorylates PI(3,4)P2 to PI(3)P.
Interaction of PI (3, 4) P2 with the pleckstrin homology (PH) domain of AKT is required for dimerization and full activation of AKT, 8 so like phosphatase and tensin homolog (PTEN), INPP4B may act as a tumour suppressor by antagonizing the PI3K/AKT signalling pathway. 9 However, recent reports demonstrated the controversial role of INPP4B in carcinogenesis in various tumours. INPP4B level was lower in follicular-like thyroid cancer tissues, melanocytic neoplasm, prostate cancer and breast cancer than in corresponding normal tissues, and knock-down of INPP4B activated AKT and increased the migratory, invasive and proliferative capacity in these cancer cells. [9] [10] [11] [12] In contrast, INPP4B was found as an oncogenic regulator in colon cancer, acute myeloid leukaemia and in a subset of melanomas. [13] [14] [15] INPP4B promoted cell proliferation and chemical resistance in these cancer cells, mainly by activating serum-and glucocorticoidregulated kinase 3 (SGK3). 13, 15 Therefore, the role of INPP4B needs to be explored in other cancer models for an overall picture of its function.
Our previous study demonstrated liver kinase B1 (LKB1) as an important tumour suppressor in cervical cancer. Overexpression of LKB1 inhibited HeLa cell proliferation and activated the AMPK pathway. 16 More importantly, overexpression of LKB1 up-regulated INPP4B and reduced p-AKT level, which suggested that LKB1 is involved in negative regulation of the PI3K/AKT pathway by INPP4B.
In this study, we further assessed the function of INPP4B in cer- 
| MATERIALS AND METHODS

| Cell lines
| Immunohistochemistry (IHC)
IHC involved the streptavidin-peroxidase-biotin IHC method according to standard procedures as we previously described. 17 Slides were incubated with primary antibody for INPP4B (1:150; Cell Signaling) overnight at 4°C. All stained slides were observed by 2 independent investigators. (Figure 2A and B) .
| Statistical analysis
Moreover, the number of invasive cells was decreased: HeLa, Figure 5F ).
| Expression of INPP4B protein in cervical tissues
We detected INPP4B in normal and cervical cancer tissues by IHC, with normal skeletal muscle tissues as a positive control ( Figure 6A ). To verify our results, we referenced the data for INPP4B mRNA expression in the Oncomine database. Two available databases, Biewenga and Scotto Cervix, had similar results as we found ( Figure 6J ).
| DISCUSSION
PI3K/AKT is a crucial pathway in carcinogenesis and is deregulated in various tumours including cervical cancer. 8, 18, 19 Mutation data from many independent studies showed mutations in PIK3CA and PTEN in various proportions in cervical cancer (13%-23% in PIK3CA,
5%-8% in PTEN)
. 20 A recent review found that HPV oncogenes E6/ E7/E5 enhance the PI3K/AKT/mTOR signalling pathway by directly activating PI3K and the downstream AKT and p70S6K, which consequently modulates tumour initiation and progression as well as patient outcome in cervical cancer. 21 As a negative regulatory molecule of the PI3K/AKT pathway, INPP4B has been reported to have tumour suppression effects in various tumours. [9] [10] [11] [12] In our previous study, we found a tumour suppressor protein, LKB1, which inhibits proliferation and up-regulates the level of INPP4B protein in cervical cancer cells. 16 This finding suggests that INPP4B, such as LKB1, may play a suppressive role in cervical cancer. In the present study, we cervical cancer cells ( Figure 3A) . Nevertheless, some recent reports have indicated that INPP4B acts as an oncogenic driver by activating SGK3 in several kinds of cancer cells. 13, 15, 24 As a member of a serine/threonine protein kinase family, SGK3 is highly homologous to and shares substrate specificity to the protein kinase B (PKB)/AKT family. 25 Tessier et al 25 pre-clinical validation for many tumour types. 28, 29 INPP4B may also be a potential candidate for adjuvant therapy of cervical cancer and other tumours that are activated in the PI3K pathway.
